SG11202110376XA - Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component - Google Patents

Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component

Info

Publication number
SG11202110376XA
SG11202110376XA SG11202110376XA SG11202110376XA SG11202110376XA SG 11202110376X A SG11202110376X A SG 11202110376XA SG 11202110376X A SG11202110376X A SG 11202110376XA SG 11202110376X A SG11202110376X A SG 11202110376XA SG 11202110376X A SG11202110376X A SG 11202110376XA
Authority
SG
Singapore
Prior art keywords
same
producing
pharmaceutical composition
effective component
heteroaryl derivative
Prior art date
Application number
SG11202110376XA
Other languages
English (en)
Inventor
Youn Ho Lee
Ju Hee Kang
Se In Kang
Hwan Kim
Seung Su Kim
Ji Yoon Seok
Yi Kyung Ko
Da Eun Kim
Ah Reum Han
Min Seok Ryu
Dong Keun Hwang
Eun Hwa Ko
Hwan Geun Choi
Sun Hwa Lee
Jung Beom Son
Nam Doo Kim
Original Assignee
Voronoi Inc
Voronoibio Inc
B2Sbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voronoi Inc, Voronoibio Inc, B2Sbio Inc filed Critical Voronoi Inc
Publication of SG11202110376XA publication Critical patent/SG11202110376XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202110376XA 2019-03-19 2020-03-19 Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component SG11202110376XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190031269 2019-03-19
KR20190134472 2019-10-28
PCT/KR2020/095044 WO2020190119A1 (fr) 2019-03-19 2020-03-19 Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace

Publications (1)

Publication Number Publication Date
SG11202110376XA true SG11202110376XA (en) 2021-10-28

Family

ID=72521153

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110376XA SG11202110376XA (en) 2019-03-19 2020-03-19 Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component

Country Status (15)

Country Link
US (2) US20220162203A1 (fr)
EP (1) EP3943491A4 (fr)
JP (2) JP7109013B2 (fr)
KR (2) KR102318875B1 (fr)
CN (3) CN115838369A (fr)
AU (2) AU2020240382B2 (fr)
BR (1) BR112021018704B1 (fr)
CA (1) CA3134261A1 (fr)
IL (2) IL299831A (fr)
MA (1) MA55380A (fr)
MX (1) MX2021011160A (fr)
NZ (1) NZ781366A (fr)
SG (1) SG11202110376XA (fr)
WO (1) WO2020190119A1 (fr)
ZA (1) ZA202107889B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299831A (en) 2019-03-19 2023-03-01 Voronoi Inc The heteroaryl derivative, a method for its production and a pharmaceutical preparation containing it as an effective ingredient
US20220289733A1 (en) * 2019-03-19 2022-09-15 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
WO2022131741A1 (fr) * 2020-12-14 2022-06-23 보로노이바이오 주식회사 Composé dérivé d'isoxazolidine et son utilisation
JP2024516721A (ja) * 2021-05-07 2024-04-16 ボロノイ インコーポレイテッド ヘテロアリール誘導体、これを製造する方法、およびこれを有効成分として含む薬学的組成物
EP4342895A1 (fr) * 2021-05-17 2024-03-27 Voronoi Inc. Composé dérivé d'hétéroaryle et son utilisation
KR102563834B1 (ko) * 2021-06-28 2023-08-04 순천대학교 산학협력단 세포자멸사를 유도하는 신규한 화합물 및 이를 포함하는 항암용 조성물
WO2024096624A1 (fr) * 2022-11-03 2024-05-10 Voronoi Inc. Sels de fumarate, tartrate, malate et de citrate d'un inhibiteur d'egfr
WO2024097848A1 (fr) * 2022-11-03 2024-05-10 Oric Pharmaceuticals, Inc. Sels de malonate et de glycolate d'un inhibiteur d'egfr

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399766T1 (de) 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
WO2005026129A1 (fr) 2003-09-15 2005-03-24 Gpc Biotech Ag Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases
EP1901747A2 (fr) 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Inhibiteurs du cdk bases sur des pyrimidines destines au traitement de la douleur
US7569561B2 (en) 2006-02-22 2009-08-04 Boehringer Ingelheim International Gmbh 2,4-diaminopyrimidines useful for treating cell proliferation diseases
CN101686675A (zh) 2007-03-20 2010-03-31 史密丝克莱恩比彻姆公司 化合物
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
JP2011102241A (ja) 2008-03-04 2011-05-26 Dainippon Sumitomo Pharma Co Ltd 新規１−アミノカルボニルピペリジン誘導体
AU2010284255B2 (en) 2009-08-17 2016-11-17 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
KR101401664B1 (ko) 2011-11-15 2014-06-11 중앙대학교 산학협력단 신경줄기세포 분화조절제용 신규 피리미딘-2,4-디아민 유도체 및 이의 의학적 용도
EP2804861B1 (fr) 2012-01-20 2018-02-28 Genosco Composés de type pyrimidine substituée et leur utilisation en tant qu'inhibiteurs des kinases syk
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
EP3680238A1 (fr) 2012-10-04 2020-07-15 University of Utah Research Foundation Analogues substitués de n-(3-(pyrimidine-4-yl)phényle)acrylamide en tant qu'inhibiteurs de btk des récepteurs de la tyrosine kinase
EP2769722A1 (fr) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Composés utilisés pour inhiber un assemblage de capside du VIH
CA2903979A1 (fr) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
AU2014309788B2 (en) 2013-08-22 2017-02-16 Taiho Pharmaceutical Co., Ltd. Novel quinoline-substituted compound
SG11201602387RA (en) 2013-10-21 2016-05-30 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
KR20150047855A (ko) 2013-10-25 2015-05-06 한미약품 주식회사 단백질 카이네이즈 억제 효과를 갖는 2-사이아노-아크릴아마이드 유도체
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
EA034691B1 (ru) 2014-06-19 2020-03-06 Ариад Фармасьютикалз, Инк. Гетероарильные соединения для ингибирования киназ
SI3205650T1 (sl) * 2014-10-11 2021-10-29 Shanghai Hansoh Biomedical Co Ltd Zaviralec EGFR-ja in priprava ter uporaba le-tega
CA2962914C (fr) * 2014-10-13 2018-10-23 Yuhan Corporation Composes et compositions destines a moduler les activites kinase de l'egfr mutant
US10059689B2 (en) * 2014-10-14 2018-08-28 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US10329277B2 (en) 2015-07-16 2019-06-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity
CN106478607B (zh) * 2015-08-28 2019-05-24 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
EP3345906B1 (fr) * 2015-08-31 2022-05-25 Wuxi Shuangliang Biotechnology Co., Ltd. 2-arylamino pyridine, dérivé de pyridine ou de triazine, leur procédé de préparation et leur utilisation
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
EP3399968B8 (fr) * 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Inhibiteurs sélectifs de mutants cliniquement importants de la tyrosine kinase de l'egfr
WO2017156527A1 (fr) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibiteurs des kinases aurora et des janus kinases pour la prévention de la maladie du greffon contre l'hôte
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
MY199042A (en) * 2017-06-13 2023-10-11 Beijing Adamadle Biotechnology Llc Aminopyrimidine compound, preparation method therefor and use thereof
US20200131176A1 (en) * 2017-07-05 2020-04-30 Cs Pharmatech Limited Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
CA3079786A1 (fr) 2017-10-24 2019-05-02 The Broad Institute, Inc. Derives de 4h-pyrrolo[3,2-c]pyridin-4-one
TWI798334B (zh) 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
CN108191774B (zh) 2018-01-31 2022-05-24 中国药科大学 一类杂环化合物、其制备方法和用途
KR20190108080A (ko) 2018-03-13 2019-09-23 보로노이바이오 주식회사 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
WO2019177375A1 (fr) 2018-03-13 2019-09-19 포로노이바이오 주식회사 Dérivés de pyrimidine substitués en positions 2, 4 et 5, leur procédé de préparation et composition pharmaceutique pour la prévention ou le traitement du cancer les contenant en tant que principe actif
EP3793993A4 (fr) 2018-05-14 2022-01-05 Takeda Pharmaceutical Company Limited Sels pharmaceutiques de dérivés de pyrimidine et méthode de traitement d'affections
CN109280048A (zh) 2018-11-16 2019-01-29 江西科技师范大学 一种含取代苯基丙烯酰胺结构的嘧啶类化合物及其应用
CN109608394A (zh) 2018-12-03 2019-04-12 湖南大学 氮杂芳胺类化合物的合成方法和氮杂芳胺类化合物
IL299831A (en) 2019-03-19 2023-03-01 Voronoi Inc The heteroaryl derivative, a method for its production and a pharmaceutical preparation containing it as an effective ingredient

Also Published As

Publication number Publication date
KR102318875B1 (ko) 2021-11-01
NZ781366A (en) 2022-08-26
IL286471A (en) 2021-12-01
JP2022125283A (ja) 2022-08-26
JP2022522250A (ja) 2022-04-14
CN113993866A (zh) 2022-01-28
CA3134261A1 (fr) 2020-09-24
EP3943491A1 (fr) 2022-01-26
MX2021011160A (es) 2022-02-10
ZA202107889B (en) 2024-02-28
AU2020240382A1 (en) 2021-11-11
CN115838369A (zh) 2023-03-24
KR20210130123A (ko) 2021-10-29
BR112021018704B1 (pt) 2023-01-10
US20220073505A1 (en) 2022-03-10
KR102564533B1 (ko) 2023-08-08
CN113993866B (zh) 2022-10-28
KR20200111644A (ko) 2020-09-29
MA55380A (fr) 2022-01-26
CN114605400A (zh) 2022-06-10
BR112021018704A2 (fr) 2021-11-23
IL299831A (en) 2023-03-01
AU2022211789A1 (en) 2022-08-25
JP7394298B2 (ja) 2023-12-08
US20220162203A1 (en) 2022-05-26
IL286471B2 (en) 2023-08-01
JP7109013B2 (ja) 2022-07-29
EP3943491A4 (fr) 2022-11-23
IL286471B1 (en) 2023-04-01
WO2020190119A1 (fr) 2020-09-24
US11466000B2 (en) 2022-10-11
AU2020240382B2 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
IL286471A (en) The heteroaryl derivative, a method for its production and a pharmaceutical preparation containing it as an effective ingredient
SG11202105850YA (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
EP3511314A4 (fr) Système de production d'une composition d'ester et procédé de production d'une composition d'ester l'utilisant
EP3312177A4 (fr) Composé dérivé tricyclique, son procédé de préparation, et composition pharmaceutique le contenant
EP3587422A4 (fr) Composé dérivé de pyrrolo-pyrimidine, son procédé de préparation, et composition pharmaceutique comprenant ledit composé en tant que principe actif pour la prévention ou le traitement d'une maladie liée à la protéine kinase
EP3580208A4 (fr) Nouveau composé hétérocyclique, son procédé de préparation et composition pharmaceutique le comprenant
EP3687540A4 (fr) Composés hétéroarylés utilisés comme inhibiteurs de cxcr4, composition et procédé d'utilisation de ceux-ci
EP3594312A4 (fr) Composition, procédé pour sa production et utilisation associée
EP3670511A4 (fr) Composé de tétrahydroprotoberbérine, son procédé de préparation, ses utilisations et composition pharmaceutique
EP3908277A4 (fr) Composés hétéroaryle utilisés comme inhibiteurs de nécrose, composition et procédé d'utilisation de ceux-ci
EP3626686A4 (fr) Composition pour verre, verre, procédé de préparation et application associés
HRP20200104T8 (hr) Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto
EP3808751A4 (fr) Dérivé de camptothécine, procédé de préparation correspondant et utilisation associée
IL286733A (en) Compound, pharmaceutical composition and method for modulating dux4 expression
IL285378A (en) A heterocyclic compound, a medical preparation containing it, a method for its preparation, and its use
EP3636281A4 (fr) Méthode de traitement de la dépression, et composition pharmaceutique
EP3838898A4 (fr) Dérivé d'isoindolin-1-one, procédé de préparation de celui-ci, et composition pharmaceutique le contenant en tant que composant actif pour la prévention ou le traitement du cancer
EP3212640A4 (fr) Composé ayant une activité agoniste gpr119, procédé pour le préparer, et composition pharmaceutique le comprenant comme constituant efficace
EP3685845A4 (fr) Composition et son procédé de production
EP3590341A4 (fr) Composition de prévention de maladies des plantes et procédé de prévention de maladies des plantes l'utilisant
EP3604303A4 (fr) Nouveau dérivé de pyrrolopyridine, son procédé de production et son utilisation
EP3650025A4 (fr) Composition pharmaceutique et sa méthode de préparation
EP3705481A4 (fr) Composés d'amide hétéroaryle, procédé de préparation de ceux-ci, compositions pharmaceutiques et applications associées
EP3689859A4 (fr) Procédé de préparation d'un dérivé d'oxaspirocycle, et d'intermédiaire de celui-ci
EP3642193A4 (fr) Composés hétéroaryle utilisés comme inhibiteurs de la nécrose, composition et procédé d'utilisation associés